2 results
Approved WMOWill not start
Primary objective:* Demonstrating clinical superiority of MOD-4023 compared to placebo in terms of reduction of fat mass (FM) in adults persons with GHDSecondary objectives:* Determining the efficacy of MOD-4023 compared to placebo in other body…
Approved WMOWill not start
Primary:To estimate the treatment effect of emactuzumab on objective response rate (ORR) by 6 months from initiation of therapy in the blinded phase compared to placeboSecondary:the effect of emactuzumab on clinical outcome assessments (COAs) for:o…